Blood Test

The new blood test screening option for colorectal cancer is innovative and could improve screening uptake, but it also has some drawbacks, according to an expert.

PHILADELPHIA — Utilization of a specialized blood test to detect Alzheimer’s-related pathology led to higher diagnostic accuracy compared to health care professionals’ identification, data show.

The FDA has approved Guardant Health’s Shield blood test to screen for colorectal cancer in patients aged 45 years and older at average risk for disease, according to a company press release.

The FDA has granted breakthrough device designation for a blood test to aid in diagnosing pneumonia and suspected lung infections in immunocompromised patients, according to a press release from the manufacturer.

Roche announced its lipoprotein(a) assay received breakthrough device designation from the FDA to identify patients with history of atherosclerotic CVD who may benefit from Lp(a)-lowering therapy currently in development.

An FDA advisory committee has voted strongly in favor of approval for Guardant Health’s blood test for colorectal cancer, intended for patients aged 45 years and older at average risk for disease.

Earlier this year, the FDA granted breakthrough device designation to Quanterix for its blood-based diagnostic assay to aid in the diagnosis of Alzheimer’s disease.

Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for Alzheimer’s disease, one which detects glial fibrillary acidic protein and another for phosphorylated tau.

A blood test successfully predicted most knee osteoarthritis cases up to 8 years before signs of the disease first appeared on X-ray, according to data published in Science Advances.